SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Di Marco A, Gaetani M, Orezzi P et al. “Daunomycin”, a new antibiotic of the rhodomycin group. Nature 1964; 201: 70607.
  • 2
    Brambilla C, Rossi A, Valagussa P et al. Adjuvant chemotherapy in postmenopausal women: results of sequential noncross-resistant regimens. World J Surg 1985; 9: 72837.
  • 3
    Fisher B, Brown A, Dimitrov N et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 1990; 8: 148396.
  • 4
    Levine MN, Pritchard KI, Bramwell VHC et al. Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada clinical trials group trial MA5. J Clin Oncol 2005; 23: 516670.
  • 5
    French Adjuvant Study Group. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of french adjuvant study group 05 randomized trial. J Clin Oncol 2001; 19: 60211.
  • 6
    Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687717.
  • 7
    Robson D, Verma S. Anthracyclines in early-stage breast cancer: is it the end of an era? Oncologist 2009; 14: 95058.
  • 8
    Piccart-Gebhart MJ, Burzykowski T, Buyse M et al. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. J Clin Oncol 2008; 26: 198086.
  • 9
    Henderson IC, Berry DA, Demetri GD et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003; 21: 97683.
  • 10
    Martin M, Pienkowski T, Mackey J et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005; 352: 230213.
  • 11
    Roche H, Fumoleau P, Spielmann M et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol 2006; 24: 566471.
  • 12
    Citron ML, Berry DA, Cirrincione C et al. Randomized trial of dose-dense versus conventionally schedules and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of intergroup trial C9741/Cancer and Leukamia Group B trial 9741. J Clin Oncol 2003; 21: 2226.
  • 13
    Sparano JA, Wang M, Martino S et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008; 358: 166371.
  • 14
    Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 78392.
  • 15
    Gennari A, Sormani MP, Pronzato P et al. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. J Natl Cancer Inst 2008; 100: 1420.
  • 16
    Wardley AM, Pivot X, Morales-Vasquez F et al. Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer. J Clin Oncol 2010 28: 97683.
  • 17
    Ardavanis A, Kountourakis P, Kyriakou F et al. Trastuzumab plus paclitaxel or docetaxel in HER-2-negative/HER-2 ECD-positive anthracycline- and taxane-refractory advanced breast cancer. Oncologist 2008; 13: 36169.
  • 18
    Nabholtz J-M, Gligorov J. Docetaxel/trastuzumab combination therapy for the treatment of breast cancer. Expert Opin Pharmacother 2005; 6: 155564.
  • 19
    Ferrans VJ. Overview of cardiac pathology in relation to anthracycline cardiotoxicity. Cancer Treat Rep 1978; 62: 95561.
  • 20
    Frishman WH, Sung HM, Yee HC et al. Cardiovascular toxicity with cancer chemotherapy. Curr Probl Cancer 1997; 21: 30160.
  • 21
    Shan K, Lincoff AM, Young JB. Anthracycline-induced cardiotoxicity. Ann Intern Med 1996; 125: 4758.
  • 22
    Giordano SH, Pinder M, Duan Z et al. Congestive heart failure (CHF) in older women treated with anthracycline (A) chemotherapy (C). J Clin Oncol (Meeting Abstracts) 2006; 24: 521.
  • 23
    Zambetti M, Moliterni A, Materazzo C et al. Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicin and breast irradiation. J Clin Oncol 2001; 19: 3743.
  • 24
    Ganz PA, Hussey MA, Moinpour CM et al. Late cardiac effects of adjuvant chemotherapy in breast cancer survivors treated on Southwest Oncology Group Protocol S8897. J Clin Oncol 2008; 26: 122330.
  • 25
    Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 167384.
  • 26
    Jones SE, Savin MA, Holmes FA et al. Phase III Trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 2006; 24: 538187.
  • 27
    Slamon D, Eiermann W, Robert N. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC-T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC-TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. In: San Antonio Breast Cancer Symp 2009.
  • 28
    Bonadonna G, Brusamolino E, Valagussa P et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 1976; 294: 40510.
  • 29
    Bonadonna G, Valagussa P, Moliterni A et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer – the results of 20 years of follow-up. N Engl J Med 1995; 332: 90106.
  • 30
    Jones S, Holmes FA, O'Shaughnessy J et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US oncology research trial 9735. J Clin Oncol 2009; 27: 117783.
  • 31
    Goldhirsch A, Wood WC, Gelber RD et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007; 18: 113344.
  • 32
    Ferguson T, Wilcken N, Vagg R et al. Taxanes for adjuvant treatment of early breast cancer. Cochrane Database Syst Rev 2007;Issue 4: Art. No.: CD004421. DOI: 10.1002/14651858.CD004421.pub2.
  • 33
    O'malley FP, Chia S, Tu D. Topoisomerase II alpha protein overexpression has predictive utility in a randomized trial comparing CMF to CEF in premenopausal women with node positive breast cancer (NCIC CTG MA. 5). Breast Cancer Res Treat 2006; 100: S18.
  • 34
    Park K, Kim J, Lim S et al. Topoisomerase II-[alpha] (topoII) and HER2 amplification in breast cancers and response to preoperative doxorubicin chemotherapy. Eur J Cancer 2003; 39: 63134.
  • 35
    Bartlett JMS, Munro A, Cameron DA et al. Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial. J Clin Oncol 2008; 26: 502735.